CDK2 and cancer: Figure 1 illustrates some important pyrazolopyridine-based compounds with potent activities for CDK2 enzyme [27,28] and its bicyclic congener Roscovitine, which is a CDK2 inhibitor undergoing clinical trials to treat cancers [29].